Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CLRB

Cellectar Biosciences Inc

Apr 14 • 04:00PM ET

2.95

+0.21 7.66 %

Healthcare • Biotechnology • USA • NASD

Apr 14, 8:40 AMCellectar Biosciences enrolls first patient in Phase 1b trial of CLR 125 for relapsed or refractory triple negative breast cancer

Peers: KPTI CBIO APTO CLLS IMUX ONCT LITS CRIS PSTV SLS

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-10.34	Insider Own	6.18%	Shs Outstand	4.24M	Perf Week	7.27%
Market Cap	12.51M	Forward P/E	-	EPS next Y	-3.04	Insider Trans	-0.08%	Shs Float	3.98M	Perf Month	-7.81%
Enterprise Value	1.62M	PEG	-	EPS next Q	-1.89	Inst Own	14.49%	Short Float	1.54%	Perf Quarter	-22.37%
Income	-21.79M	P/S	-	EPS this Y	52.34%	Inst Trans	7.11%	Short Ratio	1.55	Perf Half Y	-36.42%
Sales	0.00M	P/B	1.56	EPS next Y	23.49%	ROA	-107.74%	Short Interest	0.06M	Perf YTD	0.00%
Book/sh	1.89	P/C	0.95	EPS next 5Y	50.54%	ROE	-170.27%	52W High	20.59 -85.68%	Perf Year	-66.61%
Cash/sh	3.11	P/FCF	-	EPS past 3/5Y	60.46% 48.41%	ROIC	-213.04%	52W Low	2.43 21.40%	Perf 3Y	-92.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.53% 7.06%	Perf 5Y	-99.34%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	74.61%	Oper. Margin	-	ATR (14)	0.22	Perf 10Y	-99.97%
Dividend Ex-Date	-	Quick Ratio	2.96	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.66	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.96	EPS Q/Q	18.57%	SMA20	2.90%	Beta	0.49	Target Price	12.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	-2.46%	Rel Volume	0.96	Prev Close	2.74
Employees	11	LT Debt/Eq	0.03	Earnings	Mar 04 BMO	SMA200	-25.30%	Avg Volume	39.45K	Price	2.95
IPO	Jun 14, 2005	Option/Short	No / Yes	EPS/Sales Surpr.	153.07% -	Trades		Volume	40,335	Change	7.66%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-10-26	Upgrade	Maxim Group	Hold → Buy	$10
Dec-05-24	Resumed	Ladenburg Thalmann	Buy	$13
Jul-01-20	Initiated	Oppenheimer	Outperform
Jan-21-20	Resumed	ROTH Capital	Buy	$10
Sep-13-19	Initiated	ROTH Capital	Buy
Dec-21-16	Initiated	Ladenburg Thalmann	Buy	$2.70

Apr-14-26 08:35AM	Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) (GlobeNewswire) +7.66%
Mar-04-26 12:32PM	Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby) +8.21%
07:15AM	Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates (GlobeNewswire)
Feb-25-26 08:05AM	Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 (GlobeNewswire)
Feb-17-26 08:05AM	Cellectar Biosciences Expands Global Intellectual Property Estate (GlobeNewswire) -5.17%
08:05AM	Loading…
Jan-09-26 08:05AM	Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference (GlobeNewswire) -6.95%
Dec-16-25 08:05AM	Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies (GlobeNewswire)
Nov-13-25 04:00PM	Cellectar Biosciences Inc (CLRB) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) -18.00%
07:20AM	Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-25 08:05AM	Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 (GlobeNewswire)
Oct-27-25 08:30AM	Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma (GlobeNewswire) -10.25%
Oct-14-25 08:30AM	Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research (GlobeNewswire)
Oct-07-25 08:30AM	Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million (GlobeNewswire) -16.86%
Oct-06-25 07:00AM	Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) (GlobeNewswire) +6.75%
Sep-30-25 08:30AM	Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer (GlobeNewswire)
08:30AM	Loading…
Sep-24-25 08:30AM	Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) (GlobeNewswire) +11.15%
Sep-11-25 08:05AM	Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 (GlobeNewswire) +5.60%
Sep-09-25 08:05AM	Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit (GlobeNewswire) +5.17%
Sep-05-25 08:45AM	Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September (GlobeNewswire)
Sep-03-25 08:05AM	Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire)
Sep-02-25 09:30AM	Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands (PR Newswire)
Aug-27-25 08:05AM	Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer (GlobeNewswire)
Aug-14-25 07:19AM	Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-07-25 08:05AM	Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 (GlobeNewswire)
Jul-15-25 12:00PM	All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy (Zacks)
Jul-02-25 04:15PM	Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option (GlobeNewswire)
Jul-01-25 09:25AM	Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering (GlobeNewswire) -31.65%
Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire) -10.00%
Jun-26-25 08:05AM	Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement (GlobeNewswire) -7.05%
Jun-24-25 08:30AM	Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) (GlobeNewswire) +8.57%
04:30PM	Loading…
Jun-18-25 04:30PM	Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split (GlobeNewswire) -20.16%
Jun-11-25 08:05AM	Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma (GlobeNewswire) +16.64%
Jun-05-25 09:40AM	Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? (Zacks) -11.61%
09:00AM	Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules (GlobeNewswire)
Jun-04-25 12:35PM	What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained (Benzinga) +66.32%
08:05AM	Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) (GlobeNewswire)
May-22-25 09:36AM	Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies (Zacks)
May-21-25 11:37AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks) -5.68%
May-14-25 03:30AM	Q1 2025 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Cellectar Biosciences Inc (CLRB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-13-25 07:05AM	Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire) -9.13%
May-07-25 08:05AM	Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 (GlobeNewswire)
Apr-30-25 08:05AM	Cellectar Announces Plan to Explore Strategic Alternatives (GlobeNewswire) -13.54%
Apr-17-25 08:52AM	4 Medical Product Stocks to Buy From a Challenging Industry (Zacks) +5.58%
Mar-18-25 09:40AM	Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year? (Zacks) +11.97%
Mar-14-25 03:04AM	Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +5.34%
Mar-13-25 11:43PM	Q4 2024 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.37%
07:05AM	Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update (GlobeNewswire)
Mar-11-25 08:05AM	Cellectar Biosciences to Present at the 37th Annual Roth Conference (GlobeNewswire)
Mar-05-25 08:05AM	Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 (GlobeNewswire) +6.56%
Feb-05-25 08:05AM	Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-12-25 06:00PM	Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference (GlobeNewswire)
Dec-11-24 11:25AM	Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options (Benzinga) -76.16%
Dec-10-24 05:00PM	Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring (GlobeNewswire) -5.19%
Nov-21-24 08:00AM	NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) (Business Wire)
Nov-19-24 01:39AM	Q3 2024 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -9.04%
Nov-18-24 07:05AM	Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update (GlobeNewswire)
Nov-14-24 08:05AM	Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 (GlobeNewswire)
Nov-12-24 08:05AM	Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer (GlobeNewswire)
Nov-11-24 04:05PM	Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 (GlobeNewswire)
Nov-07-24 06:40AM	Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 (GlobeNewswire)
Nov-01-24 05:00PM	Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q (GlobeNewswire)
Aug-26-24 06:40AM	Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia (GlobeNewswire)
Aug-23-24 05:00PM	Cellectar to Restate Previously Issued Financial Statements Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq (GlobeNewswire)
Aug-13-24 06:40AM	Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update (GlobeNewswire) +8.60%
Aug-08-24 05:15PM	UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 (GlobeNewswire)
04:05PM	Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 (GlobeNewswire)
Jul-23-24 06:40AM	Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months (GlobeNewswire) -18.54%
Jul-22-24 06:40AM	Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million (GlobeNewswire) +19.84%
Jun-27-24 06:40AM	Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape (GlobeNewswire) -19.38%
May-29-24 06:40AM	Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides (GlobeNewswire)
May-15-24 08:18AM	Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.66%
03:43AM	Q1 2024 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Cellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-14-24 10:53AM	CLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024 (InvestorPlace)
06:40AM	Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update (GlobeNewswire)
May-08-24 06:40AM	Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day (GlobeNewswire)
May-07-24 06:40AM	Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 (GlobeNewswire)
Mar-28-24 10:33AM	Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.49%
Mar-27-24 10:09PM	Q4 2023 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.58%
10:53AM	CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023 (InvestorPlace)
06:40AM	Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update (GlobeNewswire)
Mar-20-24 06:40AM	Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 (GlobeNewswire)
Mar-14-24 08:52AM	Cellectar Biosciences to Present at the 36th Annual Roth Conference (GlobeNewswire)
Mar-04-24 06:40AM	Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer (GlobeNewswire)
Feb-07-24 06:40AM	Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-24 06:40AM	Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study (GlobeNewswire) -5.70%
Jan-25-24 06:40AM	Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million (GlobeNewswire) +6.85%
Jan-22-24 06:40AM	Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient (GlobeNewswire)
Jan-16-24 06:40AM	Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data (GlobeNewswire) +5.41%
Jan-12-24 06:44AM	Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results (GlobeNewswire)
Jan-11-24 06:40AM	Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting (GlobeNewswire)
Jan-08-24 08:37AM	Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today? (InvestorPlace) +18.08%
06:40AM	Cellectar's blood cancer therapy succeeds in trial (Reuters)
06:30AM	Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia (GlobeNewswire)
Jan-03-24 08:30AM	Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024 (GlobeNewswire)
Dec-19-23 08:30AM	Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation (GlobeNewswire)
Dec-12-23 08:30AM	Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform (GlobeNewswire)
Dec-05-23 08:30AM	Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe (GlobeNewswire)
Nov-04-23 12:36PM	Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript (Insider Monkey)

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
NEIS JOHN	Director	Dec 12 '25	Sale	3.70	198	732	10	Dec 16 06:00 PM
CARUSO JAMES V	Chief Executive Officer	Jul 02 '25	Buy	4.99	10,000	49,900	11,638	Jul 03 08:02 AM
Longcor Jarrod	Chief Operating Officer	Jul 02 '25	Buy	4.99	10,000	49,900	12,768	Jul 03 08:01 AM
Kolean Chad J	Chief Financial Officer	Jul 02 '25	Buy	4.99	5,000	24,950	6,418	Jul 03 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLRB

Cellectar Biosciences Inc

Upgrade your Finviz experience